EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Philip Clingan, Rahul Ladwa, Daniel Brungs, Dean Laurence Harris, Margaret McGrath, Susan Arnold, Jermaine Coward, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Andrew Mant, Vinay Sharma und 14 weitere

Journal for ImmunoTherapy of Cancer · 2023-10 · 11 (10) · e007637

DOI: 10.1136/jitc-2023-007637 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.10.2023. Verfasst von Philip Clingan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Southern Medical Day Care Centre, Wollongong, New South Wales, Australia. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Checkpoint Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab.

Methods

In this trial, participants with metastatic CSCC received cosibelimab 800 mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety.

Results

Objective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (≥15%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4/5). No treatment-related deaths were reported.

Conclusions

Cosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile. Trial registration number NCT03212404 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellSkin NeoplasmsHumansB7-H1 AntigenProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 ReceptorSkin Neoplasms

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Southern Medical Day Care Centre, Wollongong, New South Wales, Australia.
  • Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
  • Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
  • Christchurch Hospital, Christchurch, New Zealand.
  • Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
  • Exellentis Clinical Trial Consultants, George, South Africa.

ORCID-Profile: Miguel-Angel Berciano-Guerrero, James Oliviero

Förderung

  • Checkpoint Therapeutics

Zitieren

APA

Clingan, P., Ladwa, R., Brungs, D., Harris, D. L., McGrath, M., Arnold, S., Coward, J., Fourie, S., Kurochkin, A., Malan, D. R., Mant, A., Sharma, V., Shue, H., Tazbirkova, A., Berciano-Guerrero, M. A., Charoentum, C., Dalle, S., Dechaphunkul, A., Dudnichenko, O., …, & Desai, J. (2023). Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 11(10), e007637. https://doi.org/10.1136/jitc-2023-007637

Vancouver

Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, et al. Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007637. doi:10.1136/jitc-2023-007637

BibTeX
@article{Clingan2023,
  author = {Clingan, Philip and Ladwa, Rahul and Brungs, Daniel and Harris, Dean Laurence and McGrath, Margaret and Arnold, Susan and Coward, Jermaine and Fourie, Samuel and Kurochkin, Andriy and Malan, Daniel R and Mant, Andrew and Sharma, Vinay and Shue, Hong and Tazbirkova, Andrea and Berciano-Guerrero, Miguel-Angel and Charoentum, Chaiyut and Dalle, Stéphane and Dechaphunkul, Arunee and Dudnichenko, Oleksandr and Koralewski, Piotr and Lugowska, Iwona and Montaudié, Henri and Muñoz-Couselo, Eva and Sriuranpong, Virote and Oliviero, James and Desai, Jayesh},
  title = {Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {10},
  pages = {e007637},
  doi = {10.1136/jitc-2023-007637}
}
Kostenlos starten →